The L10F mutation of angiotensinogen is rare in pre-eclampsia.
Academic Article
Overview
abstract
BACKGROUND: A mutation in the gene for angiotensinogen, changing the leucine residue at position 10 to a phenylalanine (L10F), has been reported in a patient with proteinuric pre-eclampsia. In vitro enzymatic studies suggest this mutation would increase production of the vasoactive peptide, angiotensin II in vivo, and therefore explain the etiology of the maternal hypertension. OBJECTIVE: To determine whether mutation of codon 10 of angiotensinogen is common in pre-eclampsia, and therefore likely to be involved in disease susceptibility. DESIGN: We collected a cohort of 32 women with 'true' pre-eclampsia. All were normotensive prior to the 20th week of pregnancy, developed blood pressures consistently above 140/90 mmHg and had proteinuria of greater than 300 mg/day during the third trimester. All had blood pressures that returned to normal within 1 month of delivery; 31 women were primigravida. Genomic DNA was isolated from their peripheral blood lymphocytes for genetic analyses. METHODS: A polymerase chain reaction-restriction enzyme-based assay was devised to screen for mutation of codon 10 of the angiotensinogen gene. In addition, we determined the frequency of a threonine residue at position 235 in the angiotensinogen gene, given previous controversial findings of association of this polymorphism with disease. CONCLUSIONS: We detected no mutation of codon 10 in angiotensinogen in any of the 32 women studied, indicating that this mutation is not commonly associated with proteinuric pre-eclampsia. Furthermore, there was no increased frequency of threonine 235 in the affected individuals studied compared with respective normotensive Caucasian-American and African-American populations.
